Vapniarsky N, Lame M, McDonnel S and Murphy B. A lentiviral gene therapy strategy for the in vitro production of feline erythropoietin. PLoS ONE. 2012; 7: e45099. [free, full text]
In this study, the researchers wanted to investigate a possible gene delivery system for treatment of CRF-associated non-regenerative anemia that would have limited or no secondary immunogenicity, have stable and native transgene expression, and the ability to transduce both dividing and non-dividing cells. They looked at the ability of replication-incompetent lentiviral vectors to fulfill this list of requirements. They established an in vitro study system where feline erythropoietin cDNA was cloned from feline renal tissue and utilized in construction of a replication-defective lentiviral vector. The recombinant feline erythropoietin sequence was confirmed by subsequent sequencing. The results demonstrated the feasibility of this type of in vitro delivery system for the production of biologically active feline erythropoietin. In the future, cats with anemia due to CRF may benefit from a lentiviral gene therapy system. [VT]
See also: Chalhoub S, Langston CE and Farrelly J. The use of darbepoetin to stimulate erythropoiesis in anemia of chronic kidney disease in cats: 25 cases. J Vet Intern Med. 2012; 26: 363-9.
More on cat health:
Winn Feline Foundation Library
Find us on Facebook
Follow us on Twitter
Join us on Google+
No comments:
Post a Comment